Skip to content
Aminoscope
Head-to-head

KPV vs Thymosin α1

Two immune-modulating peptides at very different evidence stages — one an approved drug in dozens of countries for serious infection, the other a mouse-only anti-inflammatory fragment.

By Julian RothResearch & dataUpdated October 2026

Short answer

Thymosin α1 has the stronger evidence for its marketed use, with human clinical data against only preclinical or minimal evidence for KPV, resting mostly on animal or lab work. Someone focused on immune support has trial data to go on with thymosin α1; KPV, marketed for inflammation, gut and wound healing, is still an early-research option.

KPV

Preclinical / minimal

The anti-inflammatory tail of α-MSH, with real mechanism and real mouse data — but essentially no human trials.

Full KPV evidence review

Thymosin α1

Zadaxin

Clinical data

An approved immunomodulator in dozens of countries (for hepatitis, sepsis and severe infection, supervised) — but not FDA-approved, not the same as TB-500, and not the anti-aging injectable sold online.

Full Thymosin α1 evidence review

KPV vs Thymosin α1: head to head

FDA status / approved use

KPV

Unapproved; sold gray-market as a research peptide of unverified content

Thymosin α1

Approved as Zadaxin in dozens of countries; not FDA-approved in the US
Marketed for

KPV

Inflammation, gut, wound healing

Thymosin α1

Immune support (sold for 'anti-aging')
Outcome areas

KPV

Immune function / inflammation; Gut health; Injury recovery / tissue repair

Thymosin α1

Immune function / inflammation; Longevity / lifespan
Evidence grade

KPV

Preclinical / minimal

Thymosin α1

Clinical data
How it works

KPV

Enters cells via the PepT1 transporter and dampens inflammatory NF-κB signaling

Thymosin α1

Thymic peptide that tunes T-cell maturation and immune signaling
Route and dosing

KPV

Oral, topical or injectable products; no established dose

Thymosin α1

Injection
Headline human result

KPV

Not established

Thymosin α1

90-day transplant-free survival 75.0% vs 53.4% in a 2022 trial in hepatitis B liver failure
Strongest evidence

KPV

Dalmasso, Gastroenterology 2008. Little or no controlled human outcome data for the marketed useKPV evidence reviewPubMed 18061177

Thymosin α1

ETASS sepsis RCT, Crit Care 2013Thymosin α1 evidence reviewPubMed 23327199
Key safety signal

KPV

No human safety profile or established dose; products of unverified content

Thymosin α1

Generally well tolerated in trials; no long-term safety data for chronic use in healthy people
How it is obtained

KPV

Sold gray-market as a research chemical; no approved or legitimately compounded human product

Thymosin α1

Prescribed and dispensed by compounding pharmacies; legality varies by compound

marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.

Clinical data:
Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
Preclinical / minimal:
Evidence is largely animal, in-vitro, or anecdotal. Little or no controlled human outcome data for the marketed use.

Our verdict

Thymosin alpha-1 is a real approved immunomodulator abroad — for hepatitis, sepsis, and severe infection, under medical supervision — though it's not FDA-approved, and it isn't the same molecule as TB-500, a mix-up that happens often. KPV, the anti-inflammatory tail fragment of α-MSH, has a real mechanism and real mouse data for gut and wound-healing inflammation, but essentially no human trials exist for it at all.

KPV fits if

You're reading about the α-MSH anti-inflammatory mechanism specifically — there's no human trial behind any product sold under this name.

Thymosin α1 fits if

Serious infection or immune modulation under medical supervision is the actual context — this is the one with real approved-abroad human use, not KPV.

KPV vs Thymosin α1: common questions

Is either KPV or thymosin α1 FDA-approved?
No. KPV is unapproved; sold gray-market as a research peptide of unverified content. Thymosin α1 is approved as Zadaxin in dozens of countries; not FDA-approved in the US.
Which has stronger human evidence, KPV or thymosin α1?
Thymosin α1. It has human clinical data (key source: ETASS sepsis RCT, Crit Care 2013), while KPV has only preclinical or minimal evidence (key source: Dalmasso, Gastroenterology 2008).
What are the main safety concerns with KPV and thymosin α1?
KPV has no human safety profile or established dose; products of unverified content. Thymosin α1 is generally well tolerated in trials; no long-term safety data for chronic use in healthy people.

Key studies behind each

KPV

  1. Luger TA, Brzoska T. (2007). alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Ann Rheum Dis. PubMed 17934097
  2. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. PubMed 18061177
  3. Kelly JM, Moir AJ, Carlson K, et al. (2006). Immobilized alpha-melanocyte stimulating hormone 10-13 (GKPV) inhibits tumor necrosis factor-alpha stimulated NF-kappaB activity. Peptides. PubMed 16274845
  4. Kannengiesser K, Maaser C, Heidemann J, et al. (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. PubMed 18092346

Thymosin α1

  1. Garaci E, Pica F, Matteucci C, et al. (2024). Phenotypic drug discovery: a case for thymosin alpha-1. Front Med (Lausanne). PubMed 38903817
  2. Matteucci C, Minutolo A, Pollicita M, et al. (2010). Transcription profile of human lymphocytes following in vitro treatment with thymosin alpha-1. Ann N Y Acad Sci. PubMed 20536445
  3. Chen JF, Wu W, Yang J, et al. (2022). Safety and efficacy of Thymosin α1 in the treatment of hepatitis B virus-related acute-on-chronic liver failure: a randomized controlled trial. Hepatol Int. PubMed 35616850
  4. Peng D, Wang Z, Chen S, et al. (2020). The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis. BMC Gastroenterol. PubMed 33076834

The full evidence reviews

  • KPV peptide: what the evidence actually shows (benefits, dosage talk, and side effects)

    KPV is the anti-inflammatory tripeptide tail of α-MSH, sold for gut, inflammation, wound-healing and skin. The mechanism is real and the mouse data are real — but there are essentially no human trials. A straight read of where the science stands.

    Updated August 2026

  • Thymosin alpha-1 peptide: benefits, evidence and how it's used

    A real immune drug abroad, read against the wellness pitch. Tα1 (brand Zadaxin) is an approved immunomodulator in dozens of countries — for hepatitis, sepsis and severe infection, supervised. It is not FDA-approved, not the same as TB-500, and not the general anti-aging injectable sold online. The honest evidence, dosing and side-effect read.

    Updated October 2026

Where to get it

Where to get peptide therapy

Clinician-led telehealth services that prescribe compounded peptides. The specific peptides offered vary by provider — confirm KPV availability before ordering.

Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. How we make money.

Compare all 217 peptide-therapy providers →

Provider reviews we publish: YourHealthRxPeptiIdgie HealthRX BellaEviora MDNew Wave Health

Related comparisons